Chindex International Inc. (Nasdaq:CHDX) announced late Wednesday that it had received regulatory approval from China’s State Food and Drug Administration to sell new products, including the DaVinci S Surgical System and the AlexLaser. The company is a Bethesda, Md.-based provider of international healthcare services and Western healthcare products in China. The regulatory approval will allow Chindex to immediately begin the sales process and marketing programs, the company said.

Ahead of the opening bell Thursday, shares of Chindex International rose 17.7% to $16.49, about $2.48 above Wednesday’s close.

For detailed price information and recent news stories on Chindex International Inc., click CHDX.